Unity Biotechnology Q2 EPS $(0.85) Beats $(0.86) Estimate
Portfolio Pulse from Benzinga Newsdesk
Unity Biotechnology reported Q2 losses of $(0.85) per share, beating the analyst consensus estimate of $(0.86) by 1.16 percent. This represents a 55.26 percent increase over losses of $(1.90) per share from the same period last year.
August 08, 2023 | 10:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Unity Biotechnology's Q2 results beat analyst estimates, showing a significant improvement from last year's losses.
Unity Biotechnology reported better than expected Q2 results, with losses per share improving by 55.26% compared to the same period last year. This positive earnings surprise could lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100